2023
DOI: 10.1158/1078-0432.c.6525015.v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Data from Synergy of WEE1 and mTOR Inhibition in Mutant <i>KRAS</i>-Driven Lung Cancers

Abstract: <div>Abstract<p><b>Purpose:</b> <i>KRAS</i>-activating mutations are the most common oncogenic driver in non–small cell lung cancer (NSCLC), but efforts to directly target mutant KRAS have proved a formidable challenge. Therefore, multitargeted therapy may offer a plausible strategy to effectively treat <i>KRAS</i>-driven NSCLCs. Here, we evaluate the efficacy and mechanistic rationale for combining mTOR and WEE1 inhibition as a potential therapy for lung cancers… Show more

Help me understand this report
View published versions

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles